Loading
Dermata Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Mar 2026.
Dermata Therapeutics, Inc.: what insiders have been doing
Dermata Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 4 insiders have disclosed 6 filings since 18 October 2025.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €1,072) and 1 sale (1 insider). The totals do not cover 1 filing with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Bedoya-Toro Munera Maria E filed the largest purchase, €1,072, on 17 March 2026. Those buying include 1 senior executive.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 6 filings here. The full history, which starts in 2021, counts 3 purchases against 1 sale.
The last insider purchase was made public on 17 March 2026, 215 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 6 days. The legal deadline for a Form 4 is two business days after the transaction.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
36
Thresholds
n/a
Buy Volume
€85,900
3 ops. · all time
Sell Volume
n/a
1 ops. · all time
Who traded when
BuySaleKathleen D. Scott1 sale
Munera Maria E. Bedoya-Toro1 buy
Since the insiders bought
- +0.0%Entry US$1.19 · Close at T+90 US$1.19
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.86
Analyst consensus
1 analystsUS$4.00Target US$4.00(+365%)US$4.00
Income statement
EBITDA-US$7.8M
Net income-US$7.6M0.0% margin
Valuation
P/Book1.0x
Beta0.66
Balance sheet & cash
Market capUS$4.3M
Free Cash Flow-US$7.8M
Profitability & ownership
ROE-183.9%
ROA-89.9%
% insiders27.4%
% institutions7.9%
Last declaration on 18 August 2026
Declarations36 total
102,040 sharesCommon StockSEC:0001493152-26-039046:0
170,068 sharesCommon StockSEC:0001493152-26-039048:0
11 sharesCommon StockSEC:0001493152-26-028884:0
1,000 shares@ US$1.27100.0% of flowCommon StockSEC:0001493152-26-010630:0
Canonical exit: 18 May 2026 (T+90)
122,549 sharesCommon StockSEC:0001493152-25-029470:0
490,196 sharesCommon StockSEC:0001493152-25-029468:0
78,741 sharesCommon StockSEC:0001654954-25-000690:0
78,741 sharesCommon StockSEC:0001654954-25-000692:0
196,851 sharesCommon StockSEC:0001654954-25-000693:0
787,402 sharesCommon StockSEC:0001654954-25-000691:0
10,120 shares0Common StockSEC:0001654954-22-013530:0
30,155 shares0Common StockSEC:0001654954-22-013528:0
9,810 shares0Common StockSEC:0001654954-22-013527:0
20,654 shares0Common StockSEC:0001654954-22-013525:0
11,359 shares0Common StockSEC:0001654954-22-013526:0
9,810 shares0Common StockSEC:0001654954-22-013529:0
18,110 shares0Common StockSEC:0001654954-22-009453:0
8,602 shares0Common StockSEC:0001654954-22-009452:0
8,602 shares0Common Stock, par value $0.0001 per shareSEC:0001654954-22-009456:0
26,441 shares0Common StockSEC:0001654954-22-009455:0
8,874 shares0Common Stock, par value $0.0001 per shareSEC:0001654954-22-009457:0
9,960 shares0Common StockSEC:0001654954-22-009454:0
15,466 shares0Common StockSEC:0000905718-22-000562:0
5,031 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-22-000564:0
10,593 shares0Common StockSEC:0000905718-22-000572:0
25 of 36 declarations
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. is a dermatology-focused biotechnology company listed on NASDAQ in the United States, trading under the symbols DRMA and DRMAW. Headquartered in San Diego, California, the company was formed in December 2014 as a Delaware LLC, converted into a Delaware C-corporation in March 2021, and completed its IPO in August 2021. Its early strategy centered on prescription dermatology products and novel skin-delivery science built around a proprietary platform inspired by Spongilla lacustris. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001853816/000149315226012992/form10-k.htm))
Dermata’s lead historical asset was XYNGARI, also known as DMT310, which was studied clinically for moderate-to-severe acne. In March 2025, the company reported statistically significant results from its Phase 3 STAR-1 trial. Following that readout, management reassessed the commercial and regulatory economics of a traditional prescription-acne path. In September 2025, Dermata announced a strategic pivot away from a pure Rx model toward the development and distribution of science-backed OTC and B2B skincare products, aiming for a faster route to commercialization and a lower regulatory burden. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001853816/000149315226012992/form10-k.htm))
Read moreShow less
The company’s current strategy is to build a broader portfolio of differentiated skincare offerings for underserved conditions, with emphasis on OTC acne and adjacent dermatology indications. Dermata has described opportunities in acne, psoriasis, seborrheic dermatitis, and selected aesthetic applications, while also evaluating partnerships and licensing opportunities that could extend its pipeline. The investment case is therefore less about scale today and more about whether its delivery technology and product repositioning can create a viable commercial platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001853816/000149315226012992/form10-k.htm))
From a competitive standpoint, Dermata remains a small-cap, pre-commercial or early-commercial biotech facing intense competition from established dermatology and consumer-skin-care companies with stronger balance sheets, broader distribution, and more mature brands. Its potential edge lies in formulation/delivery differentiation and in the ability to leverage scientific credibility while moving products into channels that may reach consumers more quickly than a prescription-only model. The opportunity is real, but execution risk remains high. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001853816/000149315226012992/form10-k.htm))
Recent developments are important for investors. In January 2025, Dermata entered a clinical trial collaboration with Revance, later combined with Crown Laboratories, to evaluate XYNGARI with DAXXIFY in a Phase 2a study for axillary hyperhidrosis. In 2026, the company also saw multiple Form 4 insider transaction filings, keeping governance and ownership changes on the radar. Its latest SEC filings continue to emphasize losses, limited cash resources, and going-concern risk, which are central considerations for any investor following a NASDAQ-listed United States biotech of this size. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/drma_ex991.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
